What steps should be taken to provide a 64-year-old male with chronic right‑foot deformity from prior fractures and nerve injury, who has type 2 diabetes mellitus (on metformin, glipizide, and liraglutide) and a mildly positive anti‑double‑stranded DNA antibody, with a request for a new specialized shoe?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management Plan for 64-Year-Old Male with Chronic Foot Deformity and Type 2 Diabetes

Prescribe therapeutic footwear with custom-made insoles specifically designed to accommodate his chronic right foot deformity, as this patient is at high risk for foot ulceration (IWGDF risk 2-3) given his diabetes, foot deformity, and history of trauma with nerve injury 1, 2.

Immediate Footwear Management

Prescribe extra-depth or custom-made therapeutic shoes with custom-made insoles to accommodate the structural deformity from his childhood and adolescent fractures 2. The IWGDF 2023 guidelines strongly recommend that patients with diabetes and foot deformity receive therapeutic footwear rather than standard shoes 2. Given his chronic deformity with likely altered biomechanics from nerve injury, he requires:

  • Custom-made footwear or extra-depth shoes that accommodate the specific shape and contours of his deformed right foot
  • Custom-made insoles to redistribute plantar pressures and prevent ulceration
  • Possible toe orthoses if there are digital deformities secondary to the nerve injury 2

Critical instruction: Educate him never to walk barefoot, in socks only, or in thin-soled slippers, whether indoors or outdoors 2. This is a strong recommendation given his diabetes and foot deformity.

Diabetes Foot Risk Stratification and Monitoring

This patient falls into IWGDF risk category 2 or 3 based on:

  • Presence of significant foot deformity from prior fractures
  • History of nerve injury (likely has peripheral neuropathy)
  • Type 2 diabetes on multiple medications

Schedule foot examinations every 3-6 months (if risk 2) or every 1-3 months (if risk 3) 2. At each visit, assess for:

  • Loss of protective sensation using monofilament testing
  • Peripheral artery disease (palpate pulses, check ankle-brachial index if indicated)
  • Presence of callus, pre-ulcerative lesions, or active ulceration
  • Progression of foot deformity
  • Limited joint mobility in foot and ankle

Diabetes Management Optimization

His glucose of 122 mg/dL suggests suboptimal control. Check hemoglobin A1c immediately if not done within the past 3 months 3. Target A1c <7% to reduce risk of peripheral neuropathy progression and impaired wound healing 4, 5.

Continue metformin, glipizide, and liraglutide (Victoza), but monitor closely for:

  • Metformin: Check eGFR (currently 104, which is adequate). Monitor for lactic acidosis risk factors, especially before any contrast imaging or surgical procedures. Assess vitamin B12 levels every 2-3 years 3
  • Liraglutide: Monitor for gastrointestinal side effects and cholelithiasis (given 1.5% incidence in trials) 6

Autoimmune Workup - Low Priority

The mildly positive anti-dsDNA (10 IU/mL) with negative other autoantibodies and normal inflammatory markers (ESR 9, CRP <1) is not clinically significant and does not explain his foot pain. This is nonspecific and not diagnostic of SLE [@general knowledge].

Do not pursue rheumatology referral at this time unless:

  • ANA by IFA is strongly positive (if not already done)
  • He develops specific SLE symptoms (malar rash, serositis, arthritis, renal involvement)
  • New systemic symptoms emerge

His foot pain is mechanical from chronic deformity, not autoimmune.

Patient Education - Critical Components

Provide structured foot self-care education [@2@]:

  • Daily foot inspection for any breaks in skin, blisters, or color changes
  • Wash feet daily with careful drying between toes
  • Apply emollients to prevent dry, cracked skin
  • Cut toenails straight across
  • Immediately contact healthcare provider if any wounds, redness, or swelling develop

Emphasize consistent wear of prescribed therapeutic footwear both indoors and outdoors 2. Non-adherence is the primary reason therapeutic footwear fails to prevent ulceration.

Follow-Up Timeline

  • 2 weeks: Ensure therapeutic footwear fits properly and patient is wearing consistently
  • 1 month: Reassess A1c if not recently checked
  • 3-6 months: Comprehensive foot examination with neuropathy and vascular assessment
  • Ongoing: Every 3-6 months for foot monitoring based on final risk stratification

Common Pitfalls to Avoid

  • Do not prescribe standard diabetic shoes - he needs custom footwear for his deformity [@1

References

5
Research

Diabetic foot: evaluation and management.

Southern medical journal, 2002

Related Questions

What is the appropriate management, including sharp debridement, ocollagen matrix dressing, antibiotic therapy, and orthopedic referral, for a 43-year-old female with type 2 diabetes mellitus, diabetic peripheral neuropathy, and a 2 × 1 cm superficial plantar wound on the first metatarsal with mild edema, no erythema or drainage, stable vital signs, an A1c of 9.1 %, and leukocytosis (white‑blood‑cell count 11,800)?
In a 53‑year‑old man with type 2 diabetes mellitus, hypertension, and dyslipidaemia who is taking gliclazide 60 mg once daily and a fixed‑dose combination of vildagliptin 50 mg/metformin 1000 mg twice daily, with a rising HbA1c (6.3 % → 7.1 % → 8.1 %) and fasting blood glucose of 7.9 mmol/L, what medication adjustments should be made to improve glycaemic control?
What is the optimal wound care approach for an eschar on the heel in an older diabetic patient with peripheral arterial disease, immobility, and a history of pressure ulcers, assuming adequate arterial perfusion?
What is the recommended management for a plantar corn, including first‑line salicylic acid therapy, precautions for patients with diabetes, peripheral arterial disease, or neuropathy, and second‑line treatment options?
In an adult with type 2 diabetes, peripheral neuropathy, and possible peripheral arterial disease, what is the recommended conventional wound‑dressing regimen and low‑level laser therapy protocol for a diabetic foot ulcer?
What are the dangers of obstructive sleep apnea in a severely obese patient receiving long‑term intramuscular testosterone replacement therapy with a hematocrit near 48%?
What symptoms can result from a T7 anterior disc protrusion causing mild to moderate effacement of the spinal cord?
Do veins return deoxygenated blood to the heart?
In a patient with hyponatremia (serum sodium 126 mEq/L) and hypo‑osmolar hyponatremia (serum osmolality 269 mOsm/kg), what is the next step in management?
What is the appropriate starting dose of metformin for polycystic ovary syndrome (PCOS)?
What is the recommended dosing, monitoring, and safety considerations for Fezolinetant (Veozah) in a menopausal woman with moderate-to-severe hot flashes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.